• Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics – Fighting Autoimmune Diseases
Ahead Therapeutics - Fighting Autoimmune Diseases
 
Skip to content
  • Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics - Fighting Autoimmune Diseases
Home Strategic Alliances

Strategic Alliances

Ahead Therapeutics is always looking for new partnerships. Our company has a very light structure. We keep the planning and management of the key activities ‘in-house’, which includes the development and synthesis of liposomes for pre-clinical assays.

At the same time, we have an extensive network that serves to establish lasting and trusting collaborations with the best specialists in each subject for the development of scientific and technical activities.

Scientific & Technical Collaborations



Logotipo IGTP collaborating with Ahead Therapeutics

Institut d’Investigacions Clíniques Germans Trias i Pujol (IGTP)

 

IGTP advises Ahead Therapeutics on scientific matters and offers its facilities for in vitro and in vivo assays as well as advising its clinicians.


Institut Català de Nano-Ciència i Nano-Tecnologia (ICN2)

 

ICN2 advises Ahead Therapeutics on technical matters for liposome synthesis. Ahead has been using its facilities for manufacture of the liposomes needed for the pre-clinical phase.


Institut de Recerca Biomèdica – Lleida (IRB Lleida)

 

IRB Lleida is where Ahead is running some of the in vivo assays with NOD mice for TD1 as well as some other in vitro assays. The group is led by Dr. Joan Verdaguer.


Vall d’Hebrón Institut de Recerca (VHIR) Barcelona – Centre d’Esclerosi Múltiple de Catalunya (CEMCAT)

 

VHIR – CEMCAT is where some of the in vivo assays with EAE mice models for MS (multiple sclerosis) are taking place. The group led by Dr. Carmen Espejo has more than 15 years’ experience with that animal model, being one of the leading MS research groups in our country.


ZBM Patents SL / ZBM Business Connect

 

ZBM Patents is our partner for managing and defining the IP strategy. ZBM Business Connect has also played an important role in the creation of Ahead Therapeutics and is one of our main stakeholders.


Innoqua Toxicology SL

 

Innoqua toxicology is Ahead’s partner for defining the strategy for the pre-clinical regulatory phase. It will also prepare the scientific advisory meetings with regulatory agencies and support us with IND filing.


Asphalion

 

Asphalion is Ahead’s partner for defining the regulatory strategy on the CMC (Chemical Manufacturing & Control) pre-clinical regulatory phase. It will also prepare the scientific advisory meetings with regulatory Agencies and support us with IND filing.


Institut Català de Finances

 

ICF (Catalan Finance Institute) is contributing to Ahead’s growth by giving us support in the financial area, funding the development of our new therapy with a long-term loan

Investors & Financing
Patrons are essential for biotech companies; without financial resources it is not possible to go on. So, since our very beginning we have developed a huge network with investors to ensure that we can fund our goals. In each phase, we incorporate the appropriate type of investor: FFF + BA + FO + VCs.

It is also highly strategic for us to leverage the company. We have applied for several public calls for funding of research projects with different national and international institutions, such as CDTI; ENISA; H2020 and ICF.

The initial financing round closed in December 2017. The second financing round is currently open. If you are interested in investing, please contact us.

Partnerships


Ahead Therapeutics’ business model is based on out-licensing its own program and establishing joint-venture agreements for the development of our assets.

We are also open to partnerships for the collaborative development of certain projects as well as with third party companies that could be potential licensees.

OUT-LICENSING: early out-licensing before clinical PoC or late licensing after Clinical PoC
JOINT-VENTURE: co-development agreements: Pharma / Biotech companies

Ahead Therapeutics is open to collaboration and partnership. Please contact us.

 

Patient Association
Ahead’s main mission is to promote worldwide the prevention of Autoimmune diseases, its care and its cure. All our efforts are focused on developing a therapy that really cures instead of providing a chronic palliative treatment. We strongly belief that joining forces with Patients Associations or Research Foundations will accelerate scientific progress with the goal to make everyday life of patients with Autoimmune diseases easier, safer and healthier.

Our Company

Our Company
Privacy Policy
Terms and Conditions

Contents

Technology
Pipeline
Investors & Financing
Scientific & Technical Collaborations
Partnerships
Scientific Publications
News & Media

Latest News & Press Releases

  • New clean room facility for R&D liposome batch production
  • Ahead Therapeutics will participate in the Treg Summit – Boston- 20-22 May
  • Ahead Therapeutics will receive a NEOTEC grant

Contact AHEAD THERAPEUTICS

AHEAD THERAPEUTICS S.L.
Parc de Recerca Edificio Eureka
(Universitat Autónoma de Barcelona)
08193 Cerdanyola del Vallès

Email
Back to Top

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837515
Copyright AHEAD THERAPEUTICS S.L. 2018-2019 All rights reserved. Permissions must be obtained explicitly.
Design MOD by IDYMA WebSolutions - Your Webdesign Partner.
We have placed cookies on your device to help make this website better. Some of the cookies are essential for the site to work, others non-essential cookies (including third party) to help improve the site. By clicking ‘Accept’ on this banner, or by using our site, you accept the use of cookies. You can also view our privacy statement and learn how to control or disable them. Accept